Avalere Health LLC
04/20/2021 | Press release | Distributed by Public on 04/20/2021 10:29
Jason Hall and Tom Hess Bring Additional Vaccine Expertise to Avalere
Jason Hall joins Avalere's Policy practice as a Managing Director, Vaccine Policy, and Tom Hess joins Avalere's Market Access practice as a Principal, expanding Avalere's expertise in vaccine policy and commercialization.
'The past year has revealed how essential a grounded understanding of vaccine development and planning is for all healthcare stakeholders,' said Kelly Brantley, Policy Practice Director at Avalere Health. 'Jason's expertise in this sector will help our clients understand and adapt to the evolving immunization development market.'
'The COVID-19 pandemic has showcased the impact immunization development can have on our clients' businesses and key markets,' said Lance Grady, Market Access Practice Director at Avalere Health. 'Tom brings decades of experience and knowledge on the intricacies of global vaccine commercialization, and we know he will be an asset to our clients. We're pleased he has joined our team.'
About Jason Hall
Jason Hall joins Avalere from AstraZeneca, where he held several roles during his 15-year tenure at the company. Most recently, he served as the global commercial head, Vaccines and Infectious Disease, responsible for developing and implementing influenza and respiratory syncytial virus brand, market access, and policy strategies, including influenza pandemic preparedness. He also developed long-range plans and commercialization strategies for COVID-19 vaccines and monoclonal antibody therapies.
Jason has worked closely with clinical and medical stakeholders to generate data and insights that informed recommendation decisions through the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Previously, he led the market access, government pricing, and contract strategy teams within the Infection group at MedImmune/AstraZeneca, which included responsibility for the CDC Vaccines for Children Program contract.
He has an MBA from George Washington University and a BA from Augustana College.
'COVID-19 has presented new challenges and great successes in the vaccine world,' said Jason Hall. 'I'm excited to begin working closely with Avalere's clients to help them navigate current and future changes in the immunization development sector.'
About Tom Hess
Tom joins Avalere from Medicago, where he was the senior director of Global External Affairs. He was responsible for government relations, policy, and commercial strategy While at Medicago, he helped execute multiple vaccine joint partnerships, built the commercial structure delivered global business development funding, and led COVID-19 vaccine strategic planning. He also guided the development of a non-profit organization and received the marketing excellence award for the successful introduction of new products into the US market.
Tom has over 15 years of experience in global strategic planning and building commercial organizations, which includes 12 successful product launches. He led the global vaccine strategy development as part of the Strategic Product Planning Team at Takeda. As vice president of national vaccine retail sales at GSK, his team pioneered the introduction of vaccine access into the retail space. Tom is also the co-founder of the Global Higher Education Organization.
Tom has an MBA from the University of Chicago, an MBA from Lake Forest Graduate School of Management, and a BA from Xavier University.
'I look forward working with Avalere's clients on a variety of issues related to vaccine development and launch,' said Tom Hess. 'Avalere's extensive subject matter expertise provides healthcare organizations with an enhanced understanding of where the vaccine market is now and where it is headed.'
To receive Avalere updates, connect with us.
Avalere Health is an Inovalon company, a leading provider of cloud-based platforms empowering data-driven healthcare. We believe in the power of data, informing actionable insights, delivering meaningful impact, and driving stronger patient outcomes and business economics.